“Outcomes of patients with peritoneal-limited metastatic gastric cancer undergoing bidirectional CTx cytoreductive surgery with HIPEC.
PRECISE-SG 1, single center RWD
- mPFS 9.5
- mOS 17.5 mo
- Surgery associated with better OS.”
Gasteric cancer with peritoneal metastasis
“Intraperitoneal plus i.v. paclitaxel/S-1 vs i.v. paclitaxel/ S-1 in GC with peritoneal metastasis.
Phase 3 DRAGON-01 trial, 2:1, 222 patients
- Conversion surgery 50% vs 35%
- mOS 19.4 vs 13.9 mo
IP CTx improves outcome, no ICI used, global study?.”
Treatment of esophageal squamous cell carcinoma
“CTx plus sintilimab vs chemoradiotherapy plus sintilimab vs chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma.
PHS III SCIENCE trial
- pCR: 13 vs 47.3 vs 60%
- More TEAEs in group B
Adding ICI to nCRT looks effective, manageable AEs.”
EORTC-1203 GITC INNOVATION trial results
“Trastuzumab with or without pertuzumab for peri-op CTx of HER-2 plus GC.
EORTC-1203 GITC INNOVATION
- mpRR: 23 vs 37 vs 26%
- 3year OS rate: 75 vs 76 vs 65%
- High Tox for CTx + T + P
Negative trial, but high mpRR by adding T to CTx.”
